
    
      There is a 21 day screening period followed by 28 day cycles. Patients will continue to
      receive SAR245409 as long as there is clinical benefit or until a study withdrawal criterion
      is met. The last posttreatment visit will be 30 days after the last dose or until IMP-related
      toxicities have resolved or are deemed irreversible, whichever is later.
    
  